中国国际金融股份有限公司、高盛（中国）证券有限责任公司 关于百济神州有限公司 为子公司提供担保及子公司为子公司提供担保事项的核查意见 中国国际金融股份有限公司与高盛（中国）证券有限责任公司（高盛高华证 券有限责任公司现已更名为"高盛（中国）证券有限责任公司"，以下与中国国 际金融股份有限公司合称"联席保荐机构"）作为百济神州有限公司（以下简称"百 济神州"或"公司"）首次公开发行人民币普通股（A股）股票并在科创板上市的联 席保荐机构，根据《上海证券交易所科创板股票上市规则》《上海证券交易所科 创板上市公司自律监管指引第1号——规范运作》《上市公司监管指引第8号—— 上市公司资金往来、对外担保的监管要求》等有关规定，对百济神州为子公司提 供担保及子公司为子公司提供担保事项进行了审慎核查，具体情况如下： 一、担保情况概述 （一）担保基本情况 为满足百济神州之子公司 BeiGene Switzerland GmbH（以下简称"百济神州 瑞士"）生产经营和业务发展的需求，百济神州瑞士拟向 HSBC Bank Plc, London, Zurich Branch（以下简称"汇丰银行苏黎世分行"）申请 3,000,000 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 截至2023年6月30日止六個月 中期業績公告 百濟神州有限公司連同其子公司（「本公司」或「百濟神州」或「我們」）謹此公佈本 公司截至2023年6月30日止六個月（「報告期」）的未經審核簡明綜合業績連同2022 年相應期間的比較數字，其乃根據美國公認會計原則（「美國公認會計原則」）編製 並由本公司董事會（「董事會」）審計委員會（「審計委員會」）審閱。 財務摘要 1 • 截至2023年6月30日止六個月的收入總額較截至2022年6月30日止六個月增 加約394.9百萬美元或約60.9%至約1,043.1百萬美元。產品收入較截至2022 年6月30日止六個月增加約398.0百萬美元或約70.3%至約964.0百萬美元。 • 截至2023年6月30日止六個月的開支總額較截至2022年6月30日止六個月增 加 ...

Financial Performance - Total revenue for the six months ended June 30, 2023, increased by approximately $394.9 million or about 60.9% to approximately $1,043.1 million compared to the same period in 2022[2]. - Product revenue for the same period rose by approximately $398.0 million or about 70.3% to approximately $964.0 million[2]. - Total expenses for the six months ended June 30, 2023, increased by approximately $202.2 million or about 13.2% to approximately $1,733.0 million compared to the same period in 2022[2]. - Net loss for the six months ended June 30, 2023, decreased by approximately $271.4 million or about 27.1% to approximately $729.6 million compared to the same period in 2022[2]. - Basic and diluted loss per share for the six months ended June 30, 2023, was $0.54, a decrease of 28.0% from $0.75 for the same period in 2022[2]. Cash and Assets - Cash and cash equivalents as of June 30, 2023, were $3,410.4 million, down from $3,869.6 million as of December 31, 2022[6]. - Total assets as of June 30, 2023, amounted to $5,728.7 million, a decrease from $6,379.3 million as of December 31, 2022[6]. - Total liabilities as of June 30, 2023, were $1,930.2 million, down from $1,995.9 million as of December 31, 2022[6]. - The total equity as of June 30, 2023, was $3,798,559 thousand, a decrease from $5,196,919 thousand as of June 30, 2022, indicating a decline of about 27%[9]. Research and Development - The company has established over 120 clinical trials with more than 21,000 participants across approximately 45 regions, including over 35 pivotal or potentially registrable trials[10]. - The company has three self-developed and approved drugs, with a focus on increasing drug accessibility and affordability for cancer patients globally[10]. - Research and development expenses for the six months ended June 30, 2023, amounted to $831.348 million, up from $768.122 million in the same period of 2022, reflecting an increase of about 8%[74]. - The company has a strategic collaboration agreement with Amgen for the commercialization and development of Amgen's oncology products in China, effective January 2, 2020[39]. Collaboration and Licensing - The company received a $650,000,000 upfront payment from Novartis as part of the collaboration and licensing agreement for the development and commercialization of Tislelizumab[32]. - The company is eligible for up to $1,300,000,000 in milestone payments upon achieving regulatory milestones and up to $250,000,000 upon reaching sales milestones under the agreement with Novartis[32]. - The company expanded its collaboration with Novartis by signing an option, collaboration, and licensing agreement for the development, production, and commercialization of the investigational TIGIT inhibitor, Osemitamab, in Novartis' region[35]. Financial Obligations and Commitments - Total significant contractual obligations amount to $1.799 billion, with short-term obligations of $1.034 billion and long-term obligations of $765 million as of June 30, 2023[158]. - The company has a remaining co-development funding commitment of $549.8 million related to a collaboration agreement with Amgen for global development costs[162]. - Capital commitments as of June 30, 2023, stand at $381.2 million, primarily for the construction of production and clinical R&D facilities in New Jersey and expansions in Guangzhou and Suzhou, China[165]. Market Presence and Growth - Revenue from China was $540.828 million for the six months ended June 30, 2023, compared to $403.164 million in 2022, reflecting a growth of about 34%[98]. - Revenue from the United States increased to $362.307 million in the first half of 2023, up from $156.269 million in 2022, marking a growth of approximately 132%[98]. - The company expects continued growth driven by increased sales of Baiyueze® and Baizean® in both the U.S. and China markets[129]. Employee and Management Compensation - The company reported total compensation for key management personnel of $22.803 million for the six months ended June 30, 2023, slightly down from $23.086 million in 2022[96]. - Total employee compensation costs for the six months ended June 30, 2023, were $753 million, compared to $662.2 million for the same period in 2022[175]. Governance and Compliance - The Audit Committee consists of three independent non-executive directors, with Mr. Thomas Malley serving as the Chairman, ensuring compliance with financial reporting and internal controls[179]. - The company has implemented its own insider trading policy, which meets or exceeds the standards set forth in the Hong Kong Listing Rules[181]. Future Outlook - The company expects significant revenue growth in 2023 and beyond, with product revenue growth anticipated to exceed operating expense growth in the short term[117]. - The company continues to focus on market expansion and new product development as part of its strategic initiatives moving forward[103].

A 股代码：688235 A 股简称：百济神州 公告编号：2023-025 港股代码：06160 港股简称：百济神州 美股代码：BGNE 百济神州有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、会议召开时间：2023 年 8 月 30 日(星期三)上午 09:00-10:00 2、会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 3、会议召开方式：上证路演中心网络互动 4、投资者可于 2023 年 8 月 23 日(星期三)至 8 月 29 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 ir@beigene.com 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 百济神州有限公司（以下简称"公司"）将于 2023 年 8 月 30 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公 司 2023 年半年度经营 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2023年8月14日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事王曉 東博士，以及獨立非執行董事Margaret Han Dugan博士、Donald W. Glazer先生、 Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、Thomas Malley先生、Alessandro Riva博士、Corazon (Corsee) D. Sanders博士及易清清先 生。 審計委員會會議日期 百濟神州有限公司（「本公司」）謹此公佈，本公司董事會（「董事會」）審計委員會 的會議將於2023年8月25日（香港時間）舉行，以（其中包括）審議及批准本公司及 其附屬公司截至20 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2023年8月3日， 董事會薪酬委員會根據2016期權及激勵計劃的條款向五名承授人授出可認購合共 5,133股美國存託股份的購股權並向四百二十四名承授人授出涉及合共87,092股美 國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2023年8月3日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予五名承 授人可認購合共5,133股美國存託股份的購股權。 授出購股權詳情 購股權詳情如下： 1 授出的代價： 零 已授出購股權的行使價： 每股美國存託股份209.03 美元（約每股普通股 125.42港元） 購股權的有效期： 購股權的有效期由授出日期起計為期十年，並將 於有效期屆滿時失 ...

Financial Performance - Product revenue for the second quarter reached $554 million, representing an 82% year-over-year increase[3] - BeiGene's net loss is expected to continue narrowing in 2023, indicating improved financial performance[2] - Net loss for Q2 2023 was $38.11 million, or $0.28 per share, a decrease from a net loss of $56.57 million, or $0.42 per share, in Q2 2022[9] - Total revenue for the three months ended June 30, 2023, was $595,261 thousand, representing a significant increase from $341,572 thousand in the same period of 2022, marking a growth of approximately 74.3%[16] - Product revenue for the six months ended June 30, 2023, reached $964,036 thousand, compared to $566,084 thousand in the prior year, indicating a year-over-year increase of about 70.2%[16] - The net loss for the three months ended June 30, 2023, was $(381,137) thousand, an improvement compared to a net loss of $(565,726) thousand in the same period of 2022, showing a reduction of about 32.6%[16] Product Sales and Growth - Global sales of BeiGene's BTK inhibitor, Brukinsa, amounted to $308 million in the second quarter, a 139% year-over-year increase and a 46% quarter-over-quarter increase[3] - Sales of Baiduzhe® in the U.S. amounted to $223.5 million, representing a 152.9% increase year-over-year, driven by increased usage among CLL/SLL adult patients[6] - Baiduzhe® sales in China for Q2 2023 were $48.5 million, up 32.2% year-over-year, reflecting growth across all approved indications[6] - Baizean® sales in China reached $149.5 million, a 42.5% year-over-year increase, attributed to improved market penetration and new patient demand from insurance coverage[7] Research and Development - The company is focused on expanding its innovative oncology drug pipeline and enhancing treatment options for patients globally[2] - The company held an investor R&D day to showcase its growing and diversified innovative pipeline and differentiated R&D strategies[3] - The company aims to reduce net losses in 2023 and improve the clinical development and registration of its drug candidates[18] - The company has established a strong R&D capability and strategic partnerships to accelerate the development of its diverse drug pipeline[17] Regulatory Approvals and Collaborations - The company received a positive opinion from the European Medicines Agency (EMA) supporting the use of Tazverik for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma who have previously received platinum-based chemotherapy[4] - The FDA has accepted a supplemental New Drug Application (sNDA) for Brukinsa in combination with Obinutuzumab for the treatment of relapsed/refractory follicular lymphoma, with a decision expected in Q1 2024[4] - The company announced multiple new registrations for Baiduzhe® in China, including sNDA applications for TN CLL/SLL and WM adult patients[5] - A collaboration with InnoCare Pharma was established for the global clinical development and commercialization rights of a preclinical ADC, complementing the company's existing ADC pipeline[5] Production and Capacity Expansion - The company is building production facilities to enhance clinical and production capabilities, with anticipated completion dates and capacity improvements[2] - The company is constructing a flagship production base in New Jersey with an investment exceeding $700 million, expected to be completed in 2024, covering over 1 million square feet[13] - The company is expanding its production capacity in Suzhou, which is expected to increase small molecule drug production capacity by over 5 times upon completion[13] Financial Position - Cash, cash equivalents, restricted cash, and short-term investments totaled $3.5 billion as of June 30, 2023, down from $4.5 billion at the end of 2022[9] - The company reported total assets of $5,728,736 thousand as of June 30, 2023, a decrease from $6,379,290 thousand on December 31, 2022, representing a decline of approximately 10.2%[15] - Cash, cash equivalents, restricted cash, and short-term investments decreased to $3,527,267 thousand from $4,540,288 thousand, a reduction of about 22.3%[15] - The company’s total liabilities decreased to $1,930,177 thousand from $1,995,935 thousand, a decline of about 3.3%[15] Operating Expenses - Operating expenses for Q2 2023 were $818 million, a 15.2% increase from $709.8 million in Q2 2022, while product revenue grew significantly[9] - The total expenses for the three months ended June 30, 2023, amounted to $913,976 thousand, compared to $780,971 thousand in the same period of 2022, representing an increase of about 17.0%[16] - Research and development expenses for the three months ended June 30, 2023, were $422,764 thousand, up from $378,207 thousand in the same period of 2022, reflecting a rise of approximately 11.8%[16]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 BG ...

Financial Performance - The company's revenue for Q1 2023 reached CNY 3,066,389 thousand, representing a 57.4% increase year-over-year[4] - Product revenue accounted for CNY 2,807,965 thousand, marking a 69.0% growth compared to the same period last year[4] - The net loss attributable to shareholders was CNY -2,446,580 thousand, with a basic and diluted earnings per share of CNY -1.81[6] - Total revenue for Q1 2023 reached RMB 3,066,389 thousand, a 57.4% increase from RMB 1,947,858 thousand in Q1 2022[21] - Net loss for Q1 2023 was RMB 2,446,580 thousand, an improvement from a net loss of RMB 2,866,345 thousand in Q1 2022[22] - The total comprehensive loss for Q1 2023 was RMB -2,537,142 thousand, compared to RMB -3,063,036 thousand in Q1 2022[23] Expenses and Costs - Research and development expenses totaled CNY 2,818,146 thousand, constituting 91.9% of total revenue, a decrease of 37.3 percentage points from the previous year[6][10] - Total operating costs increased to RMB 5,640,428 thousand, up 19.5% from RMB 4,720,140 thousand in the same period last year[21] - R&D expenses rose to RMB 2,818,146 thousand, reflecting a 12% increase compared to RMB 2,516,771 thousand in Q1 2022[21] Cash Flow and Assets - The company reported a net cash flow from operating activities of CNY -3,577,897 thousand, indicating a significant cash outflow[4] - Cash flow from operating activities showed a net outflow of RMB 3,577,897 thousand, worsening from a net outflow of RMB 1,961,086 thousand in the previous year[24] - Cash and cash equivalents at the end of Q1 2023 totaled RMB 17,812,155 thousand, down from RMB 25,544,570 thousand at the end of Q1 2022[25] - The company's cash and cash equivalents were CNY 17,820,387 thousand, down from CNY 20,132,630 thousand in December 2022, representing a decline of approximately 6.5%[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 40,975,910 thousand, down 7.3% from the end of the previous year[6] - As of March 31, 2023, the company's total assets amounted to CNY 40,975,910 thousand, a decrease from CNY 44,224,173 thousand at the end of 2022[19] - The total liabilities decreased to CNY 12,377,256 thousand from CNY 13,893,114 thousand, indicating a reduction of approximately 10.9%[20] - The company's equity attributable to shareholders was CNY 28,598,654 thousand, down from CNY 30,331,059 thousand, a decline of about 5.7%[20] Shareholder Information - The company has a total of 1,362,652,101 shares issued, with 91.56% of shares held overseas[12] - The number of registered shareholders was 45,322, including 45,162 domestic shareholders and 8 American depositary share holders[15] Other Financial Activities - The company received government grants amounting to CNY 129,210 thousand during the period[7] - The total non-recurring gains and losses amounted to CNY 167,156 thousand after tax adjustments[7] - Investment activities generated a net cash inflow of RMB 1,538,416 thousand, compared to RMB 1,790,489 thousand in the same quarter last year[24] - The company received RMB 195,692 thousand from investment activities in Q1 2023, up from RMB 75,446 thousand in Q1 2022[25] Risks and Challenges - The company highlighted potential risks in drug development due to long R&D cycles and regulatory uncertainties, which may impact future performance[17]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-Q ___________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37686 B ...